Back to results
US 2026/0125410 A1Published application
Molecular degraders of extracellular proteins
OwnerDavid CAIANIELLO, Edward DERAMON +1inventors
InventorsDavid CAIANIELLO, Edward DERAMON, David SPIEGEL
Life of this patent
Estimating the term…
Abstract
The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-β1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.
Claims12
A compound of Formula I, or a pharmaceutically acceptable salt thereof, having the structure:
- wherein:
- is a connecting linker between LA and LB with the structure
- wherein LA and LB are covalently bonded to either of the open valences in
- shown by the wavy lines;
- LA is an asialoglycoprotein receptor (ASGPR) binding moiety with the structure
- LB is an anti-β1AR binding moiety with the structure
- AA is an amino acid sequence at least 80% homologous to SEQ ID NO:
- 1;
- each occurrence of RG1′ is independently
- each occurrence of RG1 is independently H or
- each occurrence of ZG is:
- AG is
- RG2 is H;
- RG3 is C(═O)CH3;
- each occurrence of XG is independently selected from the group consisting of one or more of —CH2—, —C(═O)—, —NH—, and —O—;
- m is 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;
- and
- p is 1, 2, 3, or 4.
16 more elements
Dependencies are inferred from the claim text.